US trial set for noninvasive fertility monitor:
This article was originally published in Clinica
Pheromone Sciences is to begin a multicentre, 140-patient clinical trial of its noninvasive PSC Fertility Monitor in the US. Researchers will compare the device, which predicts ovulation by measuring ion changes on the skin's surface, with current techniques for detecting fertility and ovulation. The Toronto, Ontario-based company already has marketing clearance for the device in Canada. It plans to submit a US marketing application for the test by the end of the year.
You may also be interested in...
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.